Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Targeting the Cohesive Cluster Phenotype in Chordoma via β1 Integrin Increases Ionizing Radiation Efficacy.

Harryman WL, Gard JMC, Pond KW, Simpson SJ, Heppner LH, Hernandez-Cortes D, Little AS, Eschbacher JM, Cress AE.

Neoplasia. 2017 Nov;19(11):919-927. doi: 10.1016/j.neo.2017.08.005. Epub 2017 Sep 24.


Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells.

Das L, Anderson TA, Gard JM, Sroka IC, Strautman SR, Nagle RB, Morrissey C, Knudsen BS, Cress AE.

J Cell Biochem. 2017 May;118(5):1038-1049. doi: 10.1002/jcb.25673. Epub 2017 Jan 5.


Schwann Cells Increase Prostate and Pancreatic Tumor Cell Invasion Using Laminin Binding A6 Integrin.

Sroka IC, Chopra H, Das L, Gard JM, Nagle RB, Cress AE.

J Cell Biochem. 2016 Feb;117(2):491-9. doi: 10.1002/jcb.25300.


Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals.

Geffre CP, Pond E, Pond GD, Sroka IC, Gard JM, Skovan BA, Meek WE, Landowski TH, Nagle RB, Cress AE.

Am J Transl Res. 2015 Feb 15;7(2):348-55. eCollection 2015.


Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.

Kacsinta AD, Rubenstein CS, Sroka IC, Pawar S, Gard JM, Nagle RB, Cress AE.

Biochem Biophys Res Commun. 2014 Nov 14;454(2):335-40. doi: 10.1016/j.bbrc.2014.10.073. Epub 2014 Oct 22.


Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Sroka IC, Sandoval CP, Chopra H, Gard JM, Pawar SC, Cress AE.

Mol Cancer Res. 2011 Oct;9(10):1319-28. doi: 10.1158/1541-7786.MCR-11-0080. Epub 2011 Aug 8.


ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ, Lau SS.

Toxicol Sci. 2011 Nov;124(1):75-87. doi: 10.1093/toxsci/kfr203. Epub 2011 Aug 2.


Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer.

Sroka IC, Pond GD, Nagle RB, Porreca F, King T, Pestano G, Futscher BW, Gard JM, Riley J, Cress AE.

Open Prost Cancer J. 2009 Jan 1;2:59-66.


The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.

Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G.

Clin Cancer Res. 2007 Jun 1;13(11):3388-94.


In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G.

Oncol Res. 2004;14(10):513-27.


The DRD2 TaqI polymorphism and symptoms of attention deficit hyperactivity disorder.

Rowe DC, Van den Oord EJ, Stever C, Giedinghagen LN, Gard JM, Cleveland HH, Gilson M, Terris ST, Mohr JH, Sherman S, Abramowitz A, Waldman ID.

Mol Psychiatry. 1999 Nov;4(6):580-6.


Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity.

Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C.

Am J Hum Genet. 1998 Dec;63(6):1767-76.


Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder.

Rowe DC, Stever C, Giedinghagen LN, Gard JM, Cleveland HH, Terris ST, Mohr JH, Sherman S, Abramowitz A, Waldman ID.

Mol Psychiatry. 1998 Sep;3(5):419-26.


The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children.

Rowe DC, Stever C, Gard JM, Cleveland HH, Sanders ML, Abramowitz A, Kozol ST, Mohr JH, Sherman SL, Waldman ID.

Behav Genet. 1998 May;28(3):215-25.


Supplemental Content

Support Center